Alnylam announces partnership with roche to co-develop and co-commercialize zilebesiran, an investigational rnai therapeutic for the treatment of hypertension in patients with high cardiovascular risk

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced it has entered into a strategic agreement with roche to develop and commercialize zilebesiran, alnylam's investigational rnai therapeutic for the treatment of hypertension, which is currently in phase 2 of development. the partnership allows for a bold development plan with the goal of disrupting the hypertension treatment paradigm globally while advancing alny.
ALNY Ratings Summary
ALNY Quant Ranking